Johnson & Johnson
Johnson & Johnson has finalized its acquisition of Firefly Bio, which is expected to reduce its 2026 adjusted earnings by approximately $0.46 per share.
Why it matters for sellers
M&A integration = tooling and consolidation needs
Signal details
- Counterparty
- Firefly Bio
- Reported
- July 29, 2026
- Source
- boursorama.com
From the coverage · boursorama.com
N on Wednesday lowered its 2026 earnings forecast, citing the combined financial impact of its recently finalized acquisition of Firefly Bio and a strategic partnership with Sail Biomedicines. 75. 6% in extended trading. 18. 58 billion and focuses on developing next-generation treatments for autoimmune diseases. Under the terms of the agreement, J&J will make an upfront payment of $785 million, including a $465 million equity investment in Sail. Sail could also receive up to $140 million in additional payments if it achieves certain key development milestones.
This partnership focuses on in vivo CAR-T therapies, designed to reprogram immune cells directly inside the patient's body, without the need for their extraction. 4 billion. 28 from Sail, subject to the achievement of specific development milestones and the exercise of its contractual options.
Get signals like this for every account you sell to
Our engine detects, verifies, and deduplicates thousands of buying signals every day across 50M+ companies — delivered via API, GCS push, or flat file.
More from the last 24 hours
Meta
CapEx InvestmentMeta announced a joint venture with BlackRock to create a $14 billion data center project in El Paso, Texas.
Microsoft
EarningsMicrosoft reported $90 billion in revenue for the quarter ended June 30, an 18% increase.
Boeing
New CustomerBoeing was awarded a contract modification worth up to $213,000,000 by the Naval Air Systems Command to reconfigure four P-8A Multi-mission Maritime aircraft for a Foreign Military Sales customer.
Arm
EarningsArm reported a record total revenue of $1.29 billion for its first quarter of fiscal year 2027, an increase of 22% year-over-year.